Actio gets $66M for experimental epilepsy and Charcot-Marie-Tooth treatments
Summary
Actio raised $66 million to support its experimental treatments for epilepsy and Charcot-Marie-Tooth disease. The company operates at the clinical stage and focuses on developing therapies for serious neurological conditions. The news centers on capital formation rather than a product release, acquisition, or personnel change. This round may help Actio advance research, trials, and related operational needs.
Funding
Amount
$66.0M
Total raised
Date
June 18, 2025
Announcement date
Investors
-
Lead investors
Company
actiobio.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected